Together, our findings suggest that combined blockade of IL-6 and CTLA-4 can regress pancreatic tumors via a potentially unique mechanism by imparting CD4+ and CD8+ T cell–mediated antitumor immunity. This evidence concerns the gene CTLA4 and pancreatic neoplasm.